Protara Therapeutics is trading at $2.31, down 5.53%, with broader biotech weakness a possible contributing factor. - The XBI was down 0.75% at the October 22 close; supplied sector context reports it down 2.08% during the current session. - No fresh company-specific announcement explaining the October 23 decline was identified. - The latest listed company release was October 15, about THRIVE-3 enrollment.